An Advanced Automated Patch Clamp Protocol Design to Investigate Drug-Ion Channel Binding Dynamics.
automated patch-clamp
binding kinetics
epilepsy
lidocaine
neuromuscular disorders
pain
riluzole
sodium channel inhibitor
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
07
2021
accepted:
13
09
2021
entrez:
18
10
2021
pubmed:
19
10
2021
medline:
19
10
2021
Statut:
epublish
Résumé
Standard high throughput screening projects using automated patch-clamp instruments often fail to grasp essential details of the mechanism of action, such as binding/unbinding dynamics and modulation of gating. In this study, we aim to demonstrate that depth of analysis can be combined with acceptable throughput on such instruments. Using the microfluidics-based automated patch clamp, IonFlux Mercury, we developed a method for a rapid assessment of the mechanism of action of sodium channel inhibitors, including their state-dependent association and dissociation kinetics. The method is based on a complex voltage protocol, which is repeated at 1 Hz. Using this time resolution we could monitor the onset and offset of both channel block and modulation of gating upon drug perfusion and washout. Our results show that the onset and the offset of drug effects are complex processes, involving several steps, which may occur on different time scales. We could identify distinct sub-processes on the millisecond time scale, as well as on the second time scale. Automated analysis of the results allows collection of detailed information regarding the mechanism of action of individual compounds, which may help the assessment of therapeutic potential for hyperexcitability-related disorders, such as epilepsies, pain syndromes, neuromuscular disorders, or neurodegenerative diseases.
Identifiants
pubmed: 34658875
doi: 10.3389/fphar.2021.738260
pii: 738260
pmc: PMC8513526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
738260Informations de copyright
Copyright © 2021 Lukacs, Pesti, Földi, Zboray, Toth, Papp and Mike.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Pharmacol. 2015 Sep 25;6:210
pubmed: 26441665
Br J Clin Pharmacol. 2016 Sep;82(3):673-82
pubmed: 27135195
Front Pharmacol. 2021 Aug 23;12:738460
pubmed: 34497526
Handb Exp Pharmacol. 2018;246:309-330
pubmed: 28939973
Exp Neurol. 2014 May;255:96-102
pubmed: 24613829
Curr Protoc Pharmacol. 2014 Jun 16;65:11.14.1-45
pubmed: 24934605
Cell. 2017 Jul 27;170(3):470-482.e11
pubmed: 28735751
Mol Pharmacol. 1994 May;45(5):1055-60
pubmed: 8190096
Neuropharmacology. 2011 Jan;60(1):191-200
pubmed: 20713065
Curr Top Membr. 2016;78:561-97
pubmed: 27586295
Pflugers Arch. 1991 Dec;419(6):603-9
pubmed: 1664937
Mol Pharmacol. 2006 Dec;70(6):2052-63
pubmed: 16985186
Br J Pharmacol. 2021 Mar;178(5):1200-1217
pubmed: 33450052
Neuropharmacology. 2016 Nov;110(Pt A):223-236
pubmed: 27450092
PLoS One. 2010 Dec 20;5(12):e15568
pubmed: 21187965
Front Pharmacol. 2011 Oct 14;2:63
pubmed: 22016737
Sci Rep. 2018 May 25;8(1):8110
pubmed: 29802266
Mol Pharmacol. 1994 Oct;46(4):716-25
pubmed: 7969051
Assay Drug Dev Technol. 2011 Dec;9(6):628-34
pubmed: 21675872